MX2017004127A - Methods for assessing risk of developing breast cancer. - Google Patents

Methods for assessing risk of developing breast cancer.

Info

Publication number
MX2017004127A
MX2017004127A MX2017004127A MX2017004127A MX2017004127A MX 2017004127 A MX2017004127 A MX 2017004127A MX 2017004127 A MX2017004127 A MX 2017004127A MX 2017004127 A MX2017004127 A MX 2017004127A MX 2017004127 A MX2017004127 A MX 2017004127A
Authority
MX
Mexico
Prior art keywords
methods
breast cancer
developing breast
assessing risk
risk
Prior art date
Application number
MX2017004127A
Other languages
Spanish (es)
Inventor
Allman Richard
Original Assignee
Genetic Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903898A external-priority patent/AU2014903898A0/en
Application filed by Genetic Tech Limited filed Critical Genetic Tech Limited
Publication of MX2017004127A publication Critical patent/MX2017004127A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

The present disclosure relates to methods and systems for assessing the risk of a human female subject for developing breast cancer. In particular, the present disclosure relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis, wherein the genetic risk assessment comprises screening at least (72) single nucleotide polymorphisms (SNPs) disclosed herein, or SNPs in linkage disequilibrium with one or more thereof.
MX2017004127A 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer. MX2017004127A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014903898A AU2014903898A0 (en) 2014-09-30 Methods for assessing the risk of developing breast cancer
PCT/AU2015/050583 WO2016049694A1 (en) 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer

Publications (1)

Publication Number Publication Date
MX2017004127A true MX2017004127A (en) 2017-10-24

Family

ID=55629155

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004127A MX2017004127A (en) 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer.

Country Status (11)

Country Link
US (2) US10920279B2 (en)
EP (1) EP3201360A4 (en)
JP (1) JP6820838B2 (en)
KR (1) KR102334702B1 (en)
CN (1) CN107002138B (en)
AU (2) AU2015327756B2 (en)
CA (1) CA2962691C (en)
IL (1) IL251376B (en)
MX (1) MX2017004127A (en)
SG (1) SG11201702416YA (en)
WO (1) WO2016049694A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2463388B1 (en) 2005-11-29 2017-11-22 Cambridge Enterprise Limited Markers for breast cancer
EP2438193B1 (en) 2009-06-01 2015-07-22 Genetic Technologies Limited Methods for breast cancer risk assessment
EP3201360A4 (en) 2014-09-30 2018-05-09 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
EP3574113A4 (en) * 2017-01-24 2020-10-28 Genetic Technologies Limited Improved methods for assessing risk of developing breast cancer
CA3078756A1 (en) * 2017-10-13 2019-04-18 Genetic Technologies Limited Methods of assessing risk of developing breast cancer
CN108060229A (en) * 2017-12-27 2018-05-22 沃森克里克（北京）生物科技有限公司 A kind of TERT genes rs10069690 sites SNP nucleic acid Mass Spectrometry detection methods
CN110628912A (en) * 2019-11-06 2019-12-31 上海韦翰斯生物医药科技有限公司 Primer and method for detecting polymorphism
KR102169699B1 (en) * 2019-12-27 2020-10-23 주식회사 클리노믹스 Customized DNA chip for genetic test and manufacturing method thereof)
CN112687330A (en) * 2020-12-29 2021-04-20 北京易奇科技有限公司 Risk prediction system for pathogenic variation of germ line carried by breast cancer patient
CN114283883B (en) * 2021-12-27 2022-11-22 上海华测艾普医学检验所有限公司 System for screening and risk prediction of liver cancer based on molecular marker and application

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147035A (en) 1978-05-10 1979-11-16 Minolta Camera Co Ltd Tessar type photographic lens placed behind aperture
US4240608A (en) 1979-11-02 1980-12-23 Acf Industries, Incorporated Controlled float seat arrangement for expanding gate valves
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
AU8126694A (en) 1993-10-26 1995-05-22 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
CA2257109C (en) 1996-06-04 2009-10-06 University Of Utah Research Foundation Monitoring hybridization during pcr
JP2001503276A (en) 1996-11-07 2001-03-13 オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン Breast cancer susceptibility diagnostic assay
WO2000033161A2 (en) 1998-12-02 2000-06-08 Kiva Genetics, Inc. Methods to reduce variance in treatment studies using genotyping
US20020123095A1 (en) 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
WO2002008467A1 (en) 2000-07-25 2002-01-31 Dz Genes Llc DIAGNOSTIC POLYMORPHISMS FOR THE ecNOS PROMOTER
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
WO2003012046A2 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
WO2003025141A2 (en) 2001-09-19 2003-03-27 Intergenetics Incorporated Genetic analysis for stratification of cancer risk
US20040023237A1 (en) 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6897025B2 (en) 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
US20040210400A1 (en) 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20040191783A1 (en) 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050019787A1 (en) 2003-04-03 2005-01-27 Perlegen Sciences, Inc., A Delaware Corporation Apparatus and methods for analyzing and characterizing nucleic acid sequences
US7124033B2 (en) 2003-04-30 2006-10-17 Perlegen Sciences, Inc. Method for identifying matched groups
US20040229224A1 (en) 2003-05-13 2004-11-18 Perlegen Sciences, Inc. Allele-specific expression patterns
US20040241657A1 (en) 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
US20050272043A1 (en) * 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
AU2004271164A1 (en) 2003-09-04 2005-03-17 Intergenetics, Inc. Genetic analysis for stratification of breast cancer risk
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
EP2463388B1 (en) 2005-11-29 2017-11-22 Cambridge Enterprise Limited Markers for breast cancer
JP2010512729A (en) 2006-06-23 2010-04-30 インタージェネティクス， インコーポレイテッド A genetic model for stratification of cancer risk
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
AU2008231425B2 (en) * 2007-03-26 2014-03-20 Decode Genetics Ehf Genetic variants on Chr2 and Chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EA018444B1 (en) 2007-05-25 2013-08-30 Декоуд Дженетикс Ехф. GENETIC VARIANTS ON Chr 5p12 AND 10q26 AS MARKERS FOR USE IN BREAST CANCER RISK ASSESSMENT, DIAGNOSIS, PROGNOSIS AND TREATMENT
CA2693783A1 (en) 2007-07-11 2009-01-15 Intergenetics, Inc. Genetic models for stratification of cancer risk
WO2009097270A2 (en) 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
CN102171697A (en) 2008-08-08 2011-08-31 纳维哲尼克斯公司 Methods and systems for personalized action plans
EP2335174A1 (en) 2008-09-12 2011-06-22 Navigenics INC. Methods and systems for incorporating multiple environmental and genetic risk factors
EP2438193B1 (en) * 2009-06-01 2015-07-22 Genetic Technologies Limited Methods for breast cancer risk assessment
US20120156676A1 (en) * 2009-06-25 2012-06-21 Weidhaas Joanne B Single nucleotide polymorphisms in brca1 and cancer risk
WO2013151413A1 (en) * 2012-04-02 2013-10-10 Infovalley Life Science Sdn. Bhd. Methods and compositions for determining increased risk for breast cancer
EP3201360A4 (en) 2014-09-30 2018-05-09 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
EP3574113A4 (en) 2017-01-24 2020-10-28 Genetic Technologies Limited Improved methods for assessing risk of developing breast cancer
US10609708B1 (en) 2017-06-27 2020-03-31 Sprint Spectrum L.P. Use of TDD special subframe for transmission of small quantity of data
CA3078756A1 (en) 2017-10-13 2019-04-18 Genetic Technologies Limited Methods of assessing risk of developing breast cancer

Also Published As

Publication number Publication date
AU2015327756B2 (en) 2018-01-04
EP3201360A1 (en) 2017-08-09
IL251376B (en) 2022-09-01
CA2962691A1 (en) 2016-04-07
IL251376A0 (en) 2017-05-29
US20180305764A1 (en) 2018-10-25
WO2016049694A1 (en) 2016-04-07
AU2018202299B2 (en) 2019-10-24
AU2018202299B9 (en) 2020-03-05
AU2018202299A1 (en) 2018-04-26
CN107002138B (en) 2022-06-14
SG11201702416YA (en) 2017-04-27
KR20170063977A (en) 2017-06-08
US10920279B2 (en) 2021-02-16
EP3201360A4 (en) 2018-05-09
JP2017529859A (en) 2017-10-12
AU2015327756A1 (en) 2017-04-13
KR102334702B1 (en) 2021-12-06
CA2962691C (en) 2023-05-23
US20160222469A1 (en) 2016-08-04
JP6820838B2 (en) 2021-01-27
CN107002138A (en) 2017-08-01
US10683549B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
MX2017004127A (en) Methods for assessing risk of developing breast cancer.
MX2011012913A (en) Methods for breast cancer risk assessment.
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
MX2020010947A (en) Methods of treating alzheimer's disease.
MX2009010439A (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment.
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
MX2022000289A (en) Methods of genomic evaluation in livestock.
TW201612518A (en) Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody
WO2016176451A3 (en) System and method for processing genotype information relating to nsaid risk
WO2014160876A3 (en) Brca2-specific modifier locus related to breast cancer risk
MX352296B (en) Compositions and methods for treating, diagnosing and monitoring disease.
WO2015004328A3 (en) Method and a kit for assessment of vitamin e need
UA104426U (en) The method of predicting fracture
UA95978U (en) A method for predicting fracture healing
PLOS Neglected Tropical Diseases Staff Correction: Development of Assays Using Hexokinase and Phosphoglucomutase Gene Sequences That Distinguish Strains of Leishmania tropica from Different Zymodemes and Microsatellite Clusters and Their Application to Palestinian Foci of Cutaneous Leishmaniasis
UA96535U (en) METHOD OF FORECASTING FRAGMENT FRAGMENT
UA95674U (en) METHOD OF FORECASTING FRAGMENT FRAGMENT
UA106810U (en) A method for predicting fracture healing
UA106731U (en) A method for predicting fracture healing
UA104418U (en) The method of predicting fracture
UA96593U (en) METHOD OF FORECASTING FRAGMENT FRAGMENT
WO2016094854A3 (en) Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
UA96597U (en) METHOD OF FORECASTING FRAGMENT FRAGMENT
UA96128U (en) Method for predicting fracture healing
UA97860U (en) METHOD OF FORECASTING FRAGMENT FRAGMENT